GC
FATE icon

Guggenheim Capital’s Fate Therapeutics FATE Stock Holding History

Guggenheim Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,572
Closed -$45.7K – 1895
2023
Q3 		$45.7K Sell
21,572
-35,287
-62% -$117K ﹤0.01% 1829
2023
Q2 		$271K Sell
56,859
-738
-1% -$4.07K ﹤0.01% 1689
2023
Q1 		$328K Sell
57,597
-63,320
-52% -$382K ﹤0.01% 1653
2022
Q4 		$1.22M Sell
120,917
-6,301
-5% -$118K 0.01% 1059
2022
Q3 		$2.85M Sell
127,218
-12,756
-9% -$369K 0.03% 709
2022
Q2 		$3.47M Buy
139,974
+7,599
+6% +$210K 0.03% 689
2022
Q1 		$5.13M Sell
132,375
-24,513
-16% -$949K 0.03% 641
2021
Q4 		$9.18M Buy
156,888
+17,225
+12% +$976K 0.05% 459
2021
Q3 		$8.28M Buy
139,663
+35,489
+34% +$2.78M 0.05% 454
2021
Q2 		$9.04M Sell
104,174
-1,756
-2% -$142K 0.05% 430
2021
Q1 		$8.73M Buy
105,930
+13,522
+15% +$1.3M 0.06% 412
2020
Q4 		$8.4M Buy
92,408
+34,100
+58% +$2.12M 0.05% 394
2020
Q3 		$2.33M Sell
58,308
-250
-0.4% -$8.73K 0.02% 825
2020
Q2 		$2.01M Buy
58,558
+24,690
+73% +$736K 0.02% 882
2020
Q1 		$752K Buy
33,868
+13,903
+70% +$352K 0.01% 1211
2019
Q4 		$391K Buy
19,965
+7,312
+58% +$116K ﹤0.01% 1699
2019
Q3 		$197K Buy
+12,653
New +$243K ﹤0.01% 2007
2017
Q4 		– Sell
-10,636
Closed -$43K – 2742
2017
Q3 		$43K Buy
10,636
+336
+3% +$1.14K ﹤0.01% 2707
2017
Q2 		$33K Buy
+10,300
New +$39.5K ﹤0.01% 2754

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Guggenheim Capital's FATE Position: Q4 2023 in Review

Guggenheim Capital sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 21,572 shares — an estimated $45.7K sold.

Guggenheim Capital first reported a position in FATE in Q2 2017 and held it in 19 quarters. The position peaked at $9.18M in Q4 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Guggenheim Capital reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Guggenheim Capital sold 21,572 Fate Therapeutics shares in Q4 2023, an estimated $45.7K.
  • Guggenheim Capital first reported a position in Fate Therapeutics in Q2 2017 and held it in 19 quarters.
  • Guggenheim Capital's Fate Therapeutics position peaked at $9.18M in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Guggenheim Capital's 13F filing for Q4 2023, filed 14 Feb 2024.